Breast cancer diagnosis is a multi-step process that typically starts with a screening mammogram or a physical finding, moves through diagnostic imaging, and ends with a biopsy that confirms whether cancer is present. No single test diagnoses breast cancer on its own. Each step narrows the picture until a pathologist can examine actual tissue under a microscope and deliver a definitive answer.
Screening: The First Step
Most breast cancers are caught through routine screening before any symptoms appear. The U.S. Preventive Services Task Force recommends mammography every two years for women aged 40 to 74. A screening mammogram takes X-ray images of each breast from two angles, looking for masses, unusual densities, or tiny calcium deposits called calcifications that can signal early cancer.
3D mammography (tomosynthesis) has become widely available and offers a meaningful improvement over standard 2D images. A ten-year study published by the Radiological Society of North America found that 3D mammography detected cancer in 5.3% of cases compared to 4.0% with traditional mammography, while also reducing false alarms. The recall rate, meaning the percentage of women called back for additional imaging, dropped from 10.6% to 7.2% with 3D technology. If your imaging center offers 3D mammography, it’s worth choosing.
What Happens After an Abnormal Mammogram
Radiologists score every breast image using a standardized system called BI-RADS, which ranges from 0 to 6. Understanding your score helps you know what comes next:
- BI-RADS 0: The images were incomplete or unclear. You’ll need additional scans before the radiologist can issue a final report.
- BI-RADS 1: Negative. No cancer detected.
- BI-RADS 2: Also negative, though benign findings like cysts may be noted. Routine screening continues on the normal schedule.
- BI-RADS 3: Probably benign, with roughly a 2% chance of cancer. Your doctor will typically recommend a follow-up scan in six months to confirm nothing has changed.
- BI-RADS 4: Suspicious. A biopsy is recommended. This category is subdivided further; a 4A finding carries a 2% to 10% likelihood of cancer, while higher subcategories carry greater suspicion.
- BI-RADS 5: Highly suggestive of cancer. Biopsy is essential.
- BI-RADS 6: Cancer already confirmed by prior biopsy. This score is used when imaging is done to guide treatment planning.
Getting called back after a mammogram is common and does not mean you have cancer. Most callbacks result in a benign finding.
Ultrasound and MRI: When More Imaging Is Needed
If a mammogram flags something suspicious, the next step is often a diagnostic ultrasound. Ultrasound uses sound waves to distinguish between solid masses and fluid-filled cysts, which are almost always harmless. For women under 30 with breast symptoms, ultrasound is typically the first imaging tool used rather than a mammogram, because younger breast tissue is denser and harder to read on X-ray. Any new lump you can feel should be evaluated with both a diagnostic mammogram and ultrasound.
Breast MRI is reserved for specific situations. It’s used for high-risk screening (particularly in women with known genetic risk factors), to evaluate how far a newly diagnosed cancer has spread within the breast, to investigate unexplained nipple discharge when mammography and ultrasound look normal, and to check the integrity of silicone implants. MRI is the most sensitive breast imaging tool, but it also produces more false positives, which is why it isn’t used for routine screening in average-risk women.
Biopsy: The Only Way to Confirm Cancer
Imaging can raise or lower suspicion, but only a biopsy provides a definitive diagnosis. During a biopsy, a small sample of breast tissue is removed and sent to a pathologist who examines it under a microscope. There are two main types you’re likely to encounter.
A fine needle aspiration uses a thin needle to withdraw fluid or cells from a lump. Recovery is quick: you can remove the bandage, shower, and return to normal activity the same evening. This method works well for cysts but may not collect enough tissue for a complete cancer diagnosis.
A core needle biopsy uses a slightly larger, hollow needle to remove small cylinders of tissue, giving the pathologist much more to work with. This is the standard approach for suspicious solid masses. Recovery takes a bit longer. You’ll need to keep the bandage dry for 24 hours and avoid activities that bounce or stretch the breast (like jogging) for three days. Vigorous arm activity should wait a full week, and you shouldn’t soak the biopsy site in water (baths, pools, hot tubs) for seven days. For pain relief during those first three days, stick to acetaminophen rather than anti-inflammatory drugs that can affect blood clotting.
If you take blood thinners, your care team will give you specific instructions about pausing them before the procedure.
Pathology Results and Biomarker Testing
When a biopsy confirms cancer, the work isn’t finished. The tissue sample undergoes additional lab tests to identify the cancer’s biological characteristics, which shape every treatment decision that follows.
The most important tests check for three receptors on the surface of cancer cells. Estrogen receptor (ER) and progesterone receptor (PR) testing reveals whether the cancer’s growth is fueled by hormones. About two-thirds of breast cancers are hormone receptor positive, meaning therapies that block these hormones can be effective. If a cancer is ER-positive, it is usually PR-positive as well.
HER2 testing measures levels of a protein that drives cell growth. HER2-positive cancers have too much of this protein, which makes them faster-growing but also makes them responsive to targeted therapies designed to block it. HER2-positive cancers account for roughly 15% to 20% of breast cancers.
Together, these three markers sort breast cancer into subtypes. Cancers that lack all three receptors, called triple-negative breast cancer, require different treatment strategies. Your subtype matters as much as your stage when it comes to predicting how the cancer will behave and which treatments will work best.
Staging: How Far Has It Spread?
Once cancer is confirmed and its biomarkers are known, doctors determine the stage using the TNM system, which evaluates three things: the size of the tumor (T), whether cancer has reached nearby lymph nodes (N), and whether it has spread to distant parts of the body (M).
Tumor size thresholds are precise. A T1 tumor is 20 millimeters or smaller, roughly the size of a grape or less. T2 tumors measure between 20 and 50 millimeters. T3 tumors exceed 50 millimeters. For lymph node involvement, clusters of cancer cells smaller than 0.2 millimeters in a lymph node are considered negative (N0). Anything larger begins to shift the staging upward. M1 means cancer has been found in distant organs or lymph nodes far from the breast.
Staging often involves additional imaging beyond the breast, such as CT scans, bone scans, or PET scans, depending on the initial findings. The combination of tumor size, node involvement, metastasis status, and biomarker results produces a final stage from 0 (pre-invasive) through IV (spread to distant organs), which guides the treatment plan.
Genetic Testing During Diagnosis
Some people are offered genetic testing as part of the diagnostic process, particularly for changes in the BRCA1 and BRCA2 genes. Inheriting a harmful change in either gene significantly raises lifetime breast cancer risk. Genetic testing is typically recommended when specific factors are present: a family member with a known BRCA mutation, Ashkenazi Jewish heritage, a personal or family history of breast cancer diagnosed at age 50 or younger, or a family history of ovarian cancer, male breast cancer, pancreatic cancer, or high-risk prostate cancer.
The results affect more than just the person being tested. A positive result may influence surgical decisions (some women opt for more extensive surgery to reduce future risk), and it alerts close relatives that they may want testing themselves. Genetic counseling is a standard part of this process, helping you understand what the results mean before and after testing.